Fox Run Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Fox Run Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$348K	Buy	+4,499	New	+$438K	0.06%	586
2025 Q4	–	Sell	-2,517	Closed	-$254K	–	1215
2025 Q3	$254K	Buy	+2,517	New	+$234K	0.04%	738
2025 Q2	–	Sell	-19,172	Closed	-$1.02M	–	1180
2025 Q1	$1.02M	Buy	+19,172	New	+$1.06M	0.16%	202
2023 Q4	–	Sell	-17,186	Closed	-$394K	–	983
2023 Q3	$394K	Buy	+17,186	New	+$385K	0.12%	348
2023 Q2	–	Sell	-37,950	Closed	-$677K	–	927
2023 Q1	$677K	Buy	+37,950	New	+$953K	0.22%	146

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fox Run Management's RYTM Position: Q1 2026 in Review

Fox Run Management opened a new position in Rhythm Pharmaceuticals (RYTM) in Q1 2026: 4,499 shares worth $348K. The stake represents 0.06% of the portfolio and ranks #586 among its holdings. This is a return to the name: Fox Run Management previously reported a position in RYTM as recently as Q3 2025.

Fox Run Management first reported a position in RYTM in Q1 2023 and has held it in 5 quarters since. The position peaked at $1.02M in Q1 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Fox Run Management held 4,499 shares of Rhythm Pharmaceuticals worth $348K as of Q1 2026.
Rhythm Pharmaceuticals was a new Fox Run Management position in Q1 2026.
Rhythm Pharmaceuticals made up 0.06% of Fox Run Management's portfolio in Q1 2026, its #586 holding.
Fox Run Management first reported a position in Rhythm Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
Fox Run Management's Rhythm Pharmaceuticals position peaked at $1.02M in Q1 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.